COMMODORE CAPITAL LP's Q3 2026 13F: 11 new positions, 7 exits

Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 16, 2026 · 37 reported positions · accession 0001831942-26-000052

What changed this quarter

COMMODORE CAPITAL LP's changes in reported equity positions, Q3 2026
Activity Security Weight before Weight now Change Shares Shares %
Reduced AMYLYX PHARMACEUTICALS INC (AMLX) 6.0% 4.5% −1.5 pts −3.65M sh −65%
Reduced COGENT BIOSCIENCES INC (COGT) 7.0% 3.1% −3.9 pts −1.79M sh −59%
Exited TANGO THERAPEUTICS INC (TNGX) 4.2% — −4.2 pts −2.25M sh −100%
Exited EYEPOINT INC (EYPT) 3.9% — −3.9 pts −4.6M sh −100%
Reduced DEFINIUM THERAPEUTICS INC (DFTX) 5.6% 2.1% −3.5 pts −1.3M sh −65%
New DAMORA THERAPEUTICS INC (DMRA) — 3.2% +3.2 pts +1.94M sh new
Exited DAMORA THERAPEUTICS INC (GLTO) 3.0% — −3.0 pts −1.94M sh −100%
New SURROZEN INC (SRZN) — 2.2% +2.2 pts +885K sh new
New KORSANA BIOSCIENCES INC (KRSA) — 2.2% +2.2 pts +877K sh new
New SAGIMET BIOSCIENCES INC (SGMT) — 2.1% +2.1 pts +2.76M sh new
New ADARX PHARMACEUTICALS INC (ADRX) — 1.9% +1.9 pts +1.26M sh new
Reduced ASSEMBLY BIOSCIENCES INC (ASMB) 2.3% 0.8% −1.5 pts −953K sh −67%
New ENTERA BIO LTD (ENTX) — 1.7% +1.7 pts +7.35M sh new
New ATTOVIA THERAPEUTICS INC (ATTO) — 1.5% +1.5 pts +1.16M sh new
New AGENUS INC (AGEN) — 1.5% +1.5 pts +1.99M sh new
Exited PERSPECTIVE THERAPEUTICS INC (CATX) 1.3% — −1.3 pts −6.34M sh −100%
Reduced PHARVARIS N V (PHVS) 2.9% 2.3% −0.7 pts −500K sh −35%
Reduced SPYRE THERAPEUTICS INC (SYRE) 4.5% 4.8% +0.4 pts −147K sh −17%
Reduced CELLDEX THERAPEUTICS INC NEW (CLDX) 3.0% 2.5% −0.5 pts −350K sh −26%
Exited NUVALENT INC (NUVL) 0.7% — −0.7 pts −100K sh −100%
Reduced KYMERA THERAPEUTICS INC (KYMR) 1.7% 1.5% −0.2 pts −75,000 sh −30%
Reduced LB PHARMACEUTICALS INC (LBRX) 2.9% 3.8% +0.9 pts −218K sh −15%
New RESEARCH ALLIANCE CORP IV (RACD) — 0.4% +0.4 pts +500K sh new
Reduced ALKERMES PLC (ALKS) 9.4% 9.0% −0.3 pts −125K sh −4%
New JATT III ACQUISITION CORP (JTTT) — 0.3% +0.3 pts +400K sh new
Exited RESEARCH ALLIANCE CORP III (RACC) 0.3% — −0.3 pts −500K sh −100%
New TCGX ACQUISITION CORP (TCGX) — 0.3% +0.3 pts +300K sh new
Increased INFLARX NV (IFRX) 1.0% 1.3% +0.3 pts +1.97M sh +27%
Increased RELMADA THERAPEUTICS INC (RLMD) 0.6% 0.7% +0.1 pts +925K sh +65%
Reduced TYRA BIOSCIENCES INC (TYRA) 3.6% 2.9% −0.6 pts −150K sh −8%
Exited VISTAGEN THERAPEUTICS INC (VTGN) 0.0% — 0.0 pts −2.79M sh −100%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 65.2% of the equity book

Changes in the top 10 this quarter: LBRX entered · DMRA entered · TYRA entered · DFTX left · TNGX left · EYPT left

# Security Weight before Weight now
1 RELAY THERAPEUTICS INC (RLAY) 13.4% 16.8%
2 ENLIVEN THERAPEUTICS INC (ELVN) 9.9% 11.6%
3 ALKERMES PLC (ALKS) 9.4% 9.0%
4 ALTO NEUROSCIENCE INC (ANRO) 4.3% 5.4%
5 SPYRE THERAPEUTICS INC (SYRE) 4.5% 4.8%
6 AMYLYX PHARMACEUTICALS INC (AMLX) 6.0% 4.5%
7 LB PHARMACEUTICALS INC (LBRX) 2.9% 3.8% Entered the top 10
8 DAMORA THERAPEUTICS INC (DMRA) 0.0% 3.2% Entered the top 10
9 COGENT BIOSCIENCES INC (COGT) 7.0% 3.1%
10 TYRA BIOSCIENCES INC (TYRA) 3.6% 2.9% Entered the top 10
— DEFINIUM THERAPEUTICS INC (DFTX) 5.6% 2.1% Left the top 10
— TANGO THERAPEUTICS INC (TNGX) 4.2% 0.0% Left the top 10
— EYEPOINT INC (EYPT) 3.9% 0.0% Left the top 10

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).